Reliability and validity of Turkish version of Migraine-Specific Quality of Life v2.1 questionnaire
| dc.contributor.author | Dikmen, Pinar Yalinay | |
| dc.contributor.author | Sahin, Aysenur | |
| dc.contributor.author | Aydinlar, Elif Ilgaz | |
| dc.contributor.author | Soyukibar, Tuba Erdogan | |
| dc.contributor.author | Ozge, Aynur | |
| dc.contributor.author | Karaci, Rahsan | |
| dc.contributor.author | Polat, Burcu | |
| dc.contributor.author | Sirin, Tuba Cerrahoglu | |
| dc.contributor.author | Saral, Damla Hazal | |
| dc.contributor.author | Tasdelen, Bahar | |
| dc.date.accessioned | 2026-11-05T11:06:44Z | |
| dc.date.issued | 2026 | |
| dc.description.abstract | Background: This study aims to assess whether the Turkish version of the Migraine-Specific Quality of Life Questionnaire v2.1 (MSQ v2.1) is a reliable and valid tool for evaluating the impact of migraine on daily functioning and overall quality of life. Patients and Methods: This multi-center, descriptive, prospective study included a total of 182 migraine patients between December 2023 and May 2024. All patients were assessed at two visits with a four-week interval. The Turkish MSQ v2.1 was evaluated for comprehensibility, patient-physician reliability, internal consistency, test-retest reliability, and construct validity. Results: Of a total of 182 patients, 19 were male and 163 were female with a mean age of 40.8 +/- 12.2 (range, 18 to 73) years. Item comprehensibility was high, with 94 to 97.8% at Visit 1, and from 98.4 to 100% at Visit 2. A strong correlation was observed between self-administered and physician-administered MSQ v2.1 scores at Visit 1 (r = 0.916, p < 0.001). Internal consistency was excellent, with Cronbach's alpha values of 0.932 at Visit 1 and 0.912 at Visit 2. Test-retest reliability was moderate (r = 0.468, p < 0.001). Construct validity was supported by strong correlations with the Headache Impact Test-6 (r = 0.751 at Visit 1 and r = 0.772 at Visit 2), monthly headache days (r = 0.453 and 0.553), and Numeric Rating Scale scores (r = 0.539 and 0.564), all with p < 0.001. Conclusion: The Turkish MSQ v2.1 is a reliable and valid tool for assessing health-related quality of life (HRQL) in migraine patients. It demonstrates excellent internal consistency, moderate test-retest reliability, and strong correlations with established measures of HRQL, headache severity, migraine frequency, and supporting its use in clinical practice and research. | |
| dc.description.issue | 2 | |
| dc.description.pages | 83-95 | |
| dc.description.volume | 38 | |
| dc.identifier.doi | 10.5606/agri.2026.21 | |
| dc.identifier.issn | 1300-0012 | |
| dc.identifier.uri | https://doi.org/10.5606/agri.2026.21 | |
| dc.identifier.uri | https://openaccess.acibadem.edu.tr/handle/11443/11379 | |
| dc.identifier.wos | WOS:001820679400004 | |
| dc.language.iso | en | |
| dc.publisher | KARE PUBL | |
| dc.relation.hasversion | 10.5606/agri.2026.21 | |
| dc.relation.ispartof | AGRI-THE JOURNAL OF THE TURKISH SOCIETY OF ALGOLOGY | |
| dc.subject | Clinical scale | |
| dc.subject | Health-Related Quality of Life | |
| dc.subject | migraine | |
| dc.subject | Migraine-Specific Quality of Life Questionnaire | |
| dc.subject | reliability | |
| dc.subject | validity | |
| dc.subject | ASSESSMENT MIDAS QUESTIONNAIRE | |
| dc.subject | CONTROLLED-TRIALS | |
| dc.subject | DISABILITY | |
| dc.subject | MSQ | |
| dc.subject | GUIDELINES | |
| dc.subject | Medicine, General & Internal | |
| dc.subject | General & Internal Medicine | |
| dc.title | Reliability and validity of Turkish version of Migraine-Specific Quality of Life v2.1 questionnaire | |
| dc.type | Article | |
| oaire.citation.edition | Emerging Sources Citation Index (ESCI) | |
| oaire.citation.endPage | 95 | |
| oaire.citation.issue | 2 | |
| oaire.citation.startPage | 83 | |
| oaire.citation.volume | 38 | |
| person.identifier.rid | G-4291-2015 | |
| person.identifier.rid | AAD-8167-2021 | |
| person.identifier.rid | D-2590-2015 | |
| person.identifier.rid | ABE-8217-2021 | |
| person.identifier.rid | AFB-2183-2022 | |
| person.identifier.rid | PLR-7263-2026 |
